Section Arrow
Quote
ZLAB.NASDAQ
- Zai Lab Limited
Quotes are at least 15-min delayed:2026/08/07 07:47 EDT
Pre Market
Last
 21.6
+0.72 (+3.45%)
Bid
21.51
Ask
21.88
High 22.12 
Low 19.5 
Volume 12.48K 
Regular Hours (Closed)
Last
 20.88
+2.51 (+13.66%)
Day High 
21.8 
Prev. Close
18.37 
1-M High
20.9 
Volume 
1.39M 
Bid
21.51
Ask
21.88
Day Low
18.845 
Open
19.05 
1-M Low
17.92 
Market Cap 
2.07B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 18.6 
20-SMA 19.41 
50-SMA 18.59 
52-W High 36.77 
52-W Low 15.96 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.70/-0.24
Enterprise Value
2.09B
Balance Sheet
Book Value Per Share
5.86
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
460.16M
Operating Revenue Per Share
2.33
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ENSCEnsysce Biosciences0.5243+0.1623+44.83%-- 
Pre Market 0.4855 -0.0388 -7.40%
CELZCreative Medical Technology Holdings1.15+0.4812+71.95%-- 
Pre Market 1.3398 +0.1898 +16.50%
IOVAIovance Biotherapeutics6.21+1.87+43.09%-- 
Pre Market 6.28 +0.07 +1.13%
GERNGeron Corp1.57-0.06-3.68%-- 
Pre Market 1.56 -0.01 -0.64%
RXRXRecursion Pharmaceuticals3.18+0.01+0.32%-- 
Pre Market 3.2085 +0.0285 +0.90%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.